Stephanie Wagner, MD
Medical Oncology · Newburgh, INNPI 1376680876
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,024 of the $1,219 with a category attached, or 84.0%. It is spread thinly across 25 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $394 and has fallen 73.2% since, to $106 in 2025. That places this record below the midpoint for medical oncology clinicians in IN, where the typical reported total is $2,472.
Across 57 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$183
- Johnson & Johnson$150
- Sanofi$82
- Novartis$81
- AstraZeneca$77
- Stryker$64
- plus $583 from 19 others
What the payments were for
- Food & beverage$1,02484%
- Education$19516%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 7 | $183 |
| Johnson & Johnson | 4 | $150 |
| Sanofi | 4 | $82 |
| Novartis | 4 | $81 |
| AstraZeneca | 4 | $77 |
| Stryker | 1 | $64 |
| Daiichi Sankyo Inc. | 3 | $63 |
| Genentech USA, Inc. | 3 | $56 |
| Merck | 3 | $55 |
| Amgen | 3 | $48 |
| Puma Biotechnology, Inc. | 2 | $44 |
| Bristol Myers Squibb | 2 | $41 |
| Adaptive Biotechnologies Corporation | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 3 | $40 |
| Ipsen Biopharmaceuticals, Inc | 2 | $37 |
| Beigene USA, Inc. | 1 | $27 |
| Seagen Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
| EMD Serono, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Array Biopharma Inc | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Gilead | 1 | $12 |
How this compares
$1,219 in reported general payments places this provider in the 35th percentile of 67 medical oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 23 | $124,234 |
| EliquisApixaban | 18 | $13,309 |
| ProcritEpoetin Alfa | 11 | $12,168 |
| XareltoRivaroxaban | 12 | $6,625 |
| Fentanyl | 28 | $4,066 |
| Letrozole | 66 | $2,436 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 40 | $993 |
| Anastrozole | 60 | $825 |
| Ondansetron OdtOndansetron | 34 | $773 |
| Hydrocortisone | 21 | $650 |
| Dexamethasone | 23 | $575 |
| Olanzapine | 23 | $551 |
| Potassium Chloride | 24 | $507 |
| Gabapentin | 48 | $500 |
| Duloxetine Hcl | 11 | $348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonProcrit, Xarelto | $150 | $18,79323 claims |
| PfizerEliquis | $183 | $13,30918 claims |
| Lilly USA, LLCOlanzapine | $15 | $55123 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $12 | $11212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 67 medical oncology providers in Indiana.
Other medical oncology in Newburgh
- Sara TariqNewburgh$955
- Costantine AlbanyLafayette$212K
- Sunil BabuFort Wayne$166K
- Natraj AmmakkanavarIndianapolis$129K
- Rafat AnsariMishawaka$90K
- Bert OneilIndianapolis$89K
- Pablo BedanoIndianapolis$52K
- Gregory SmithIndianapolis$46K
- Ashwin VasudevamurthyIndianapolis$44K
- Eduardo BraunWestville$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.